+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Epidermolysis Bullosa Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 136 Pages
  • July 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5645054
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 4, 11, 2, 2, 13, 9 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Epidermolysis Bullosa - Overview
  • Epidermolysis Bullosa - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Epidermolysis Bullosa - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Epidermolysis Bullosa - Companies Involved in Therapeutics Development
  • Epidermolysis Bullosa - Drug Profiles
  • Epidermolysis Bullosa - Dormant Projects
  • Epidermolysis Bullosa - Discontinued Products
  • Epidermolysis Bullosa - Product Development Milestones
  • Featured News & Press Releases
  • Jul 26, 2022: InMed enrols first adolescent in Phase II epidermolysis bullosa trial
  • Jun 22, 2022: Krystal Biotech submits biologics license application to U.S. FDA seeking approval of B-VEC for the treatment of patients with dystrophic epidermolysis bullosa
  • May 23, 2022: Phoenix Tissue Repair report positive Phase II epidermolysis bullosa drug trial data
  • May 19, 2022: Krystal Biotech to present additional data on B-VEC from the GEM-3 Phase 3 study at the Society for Investigative Dermatology Annual Meeting
  • May 18, 2022: Tetra Bio-Pharma receives EMA Orphan Drug Designation for a novel topical therapeutic containing CBD
  • Apr 11, 2022: Krystal Biotech announces home dosing in B-VEC open label extension study
  • Mar 28, 2022: Krystal Biotech announces publication of phase 1 and 2 clinical trial (GEM 1/2 Study) of beremagene geperpavec (B-VEC) data in Nature Medicine
  • Mar 26, 2022: New GEM-3 phase 3 results for B-VEC presented at 2022 American Academy of Dermatology Annual Meeting
  • Mar 18, 2022: Krystal Biotech to present at 2022 American Academy of Dermatology annual meeting
  • Mar 14, 2022: Abeona Therapeutics achieves target enrollment in pivotal phase 3 VIITAL study of EB-101 in RDEB
  • Nov 30, 2021: Krystal’s dystrophic EB gene therapy trial meets primary goal
  • Nov 18, 2021: Abeona Therapeutics announces support of EB research partnership's venture into cures event to raise awareness for education and research of epidermolysis bullosa
  • Oct 26, 2021: Krystal Biotech announces completion of the GEM-3 pivotal phase 3 study evaluating B-VEC for the treatment of dystrophic epidermolysis bullosa
  • Oct 21, 2021: Castle Creek Biosciences awarded FDA Orphan products development grant to support DeFi-RDEB, a pivotal phase 3 study of FCX-007 investigational gene therapy for recessive dystrophic epidermolysis bullosa
  • Sep 30, 2021: InMed Pharmaceuticals announces commencement of phase 2 clinical trial investigating cannabinol (CBN), a rare cannabinoid, in the treatment of epidermolysis bullosa
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Epidermolysis Bullosa, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Companies, 2022 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Companies, 2022 (Contd..1)
  • Products under Development by Companies, 2022 (Contd..2)
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, 2022
  • Epidermolysis Bullosa - Pipeline by Almirall SA, 2022
  • Epidermolysis Bullosa - Pipeline by Amniotics AB, 2022
  • Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, 2022
  • Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by Avicanna Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Berg LLC, 2022
  • Epidermolysis Bullosa - Pipeline by Biomendics LLC, 2022
  • Epidermolysis Bullosa - Pipeline by Branca Bunus Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by Carocell Bio Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Celularity Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Constant Therapeutics LLC, 2022
  • Epidermolysis Bullosa - Pipeline by CSA Biotechnologies LLC, 2022
  • Epidermolysis Bullosa - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by Eloxx Pharmaceuticals Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Energenesis Biomedical Co Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by FIBRX Derm Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Holostem Terapie Avanzate SRL, 2022
  • Epidermolysis Bullosa - Pipeline by Immusoft Corp, 2022
  • Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Kangstem Biotech Co Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, 2022
  • Epidermolysis Bullosa - Pipeline by LambdaGen Therapeutics, 2022
  • Epidermolysis Bullosa - Pipeline by Mariposa Therapeutics Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by Onconova Therapeutics Inc, 2022
  • Epidermolysis Bullosa - Pipeline by OTR3 SAS, 2022
  • Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, 2022
  • Epidermolysis Bullosa - Pipeline by Panag Pharma Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Phoenix Tissue Repair Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Quoin Pharmaceuticals Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Relief Therapeutics Holding AG, 2022
  • Epidermolysis Bullosa - Pipeline by RHEACELL GmbH & Co KG, 2022
  • Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, 2022
  • Epidermolysis Bullosa - Pipeline by StemRIM Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Therapicon Srl, 2022
  • Epidermolysis Bullosa - Pipeline by TWi Biotechnology Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Vera Therapeutics Inc, 2022
  • Epidermolysis Bullosa - Pipeline by Wings Therapeutics, 2022
  • Epidermolysis Bullosa - Dormant Projects, 2022
  • Epidermolysis Bullosa - Dormant Projects, 2022 (Contd..1)
  • Epidermolysis Bullosa - Discontinued Products, 2022

List of Figures
  • Number of Products under Development for Epidermolysis Bullosa, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Top 10 Routes of Administration, 2022
  • Number of Products by Stage and Top 10 Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abeona Therapeutics Inc
  • Aegle Therapeutics Corp
  • Almirall SA
  • Amniotics AB
  • Amryt Pharma Plc
  • Anterogen Co Ltd
  • Avicanna Inc
  • Berg LLC
  • Biomendics LLC
  • Branca Bunus Ltd
  • Carocell Bio Ltd
  • Castle Creek Biosciences Inc
  • Celularity Inc
  • Constant Therapeutics LLC
  • CSA Biotechnologies LLC
  • Daewoong Pharmaceutical Co Ltd
  • Eloxx Pharmaceuticals Inc
  • Energenesis Biomedical Co Ltd
  • FIBRX Derm Inc
  • Holostem Terapie Avanzate SRL
  • Immusoft Corp
  • InMed Pharmaceuticals Inc
  • Kangstem Biotech Co Ltd
  • Krystal Biotech Inc
  • LambdaGen Therapeutics
  • Mariposa Therapeutics Ltd
  • Onconova Therapeutics Inc
  • OTR3 SAS
  • Palvella Therapeutics LLC
  • Panag Pharma Inc
  • Phoenix Tissue Repair Inc
  • Quoin Pharmaceuticals Ltd
  • RegeneRx Biopharmaceuticals Inc
  • Relief Therapeutics Holding AG
  • RHEACELL GmbH & Co KG
  • Shionogi & Co Ltd
  • StemRIM Inc
  • Therapicon Srl
  • TWi Biotechnology Inc
  • Vera Therapeutics Inc
  • Wings Therapeutics